Capital Analysts, LLC Geron Corp Transaction History
Capital Analysts, LLC
- $2.49 Billion
- Q4 2024
Shares
3 transactions
Others Institutions Holding GERN
# of Institutions
306Shares Held
465MCall Options Held
1.07MPut Options Held
648K-
Black Rock Inc. New York, NY46.6MShares$110 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA33.5MShares$79.5 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA30MShares$71.1 Million1.72% of portfolio
-
Vivo Capital, LLC Palo Alto, CA27.2MShares$64.5 Million18.81% of portfolio
-
State Street Corp Boston, MA27.2MShares$64.4 Million0.0% of portfolio
About GERON CORP
- Ticker GERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 377,819,008
- Market Cap $895M
- Description
- Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...